Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 61, No. 1, 2009
Issue release date: April 2009
Section title: Original Paper
Free Access
Folia Phoniatr Logop 2009;61:1–11

Analysis of Diadochokinesis in Ataxic Dysarthria Using the Motor Speech Profile Program™

Wang Y.-T.a · Kent R.D.b · Duffy J.R.c · Thomas J.E.c
aSchool of Dentistry, National Yang-Ming University, Taipei, Taiwan; bWaisman Center, University of Wisconsin-Madison, Madison, Wisc., and cMayo Clinic, Rochester, Minn., USA
email Corresponding Author

Yu-Tsai Wang

School of Dentistry, Rm. 411, National Yang-Ming University

No. 155, Sec. 2, Li-Nong St. Beitou District

Taipei, 11211 (Taiwan)

Tel. +886 2 2826 7237, Fax +886 2 2826 4053, E-Mail yutsaiwang@ym.edu.tw

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Aims: The Diadochokinetic Rate Analysis (DRA) in the KayPENTAX Motor Speech Profile is a computer program for the analysis of diadochokinesis (DDK). The objective of this study is to evaluate the suitability, reliability, and concurrent validity of the results from the DRA protocol and hand measurement for individuals with ataxic dysarthria, which is characteristically associated with dysdiadochokinesis. Methods: Twenty-one participants with ataxic dysarthria were recorded as they repeated various syllables as quickly and steadily as possible. The DDK samples were executed by the DRA protocol at different thresholds and were also hand-measured. Analyses were based on the percentage of nonexecutable DDK samples, defined as samples in which the lowest peak intensity during CV syllables is lower than the highest peak intensity during intersyllable pauses, and the comparisons of the results between repeated analyses at different thresholds and between automatic and manual measuring methods. Results: (1) More than one third of the DDK samples were nonexecutable; (2) the reliability at different thresholds and concurrent validity between different measuring methods were both satisfactory, and (3) temporal variation parameters were more inconsistent between different measuring methods than intensity variation parameters. Conclusion: DRA has notable limitations in its clinical application but there is a considerable potential for improving its performance.

© 2008 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: December 17, 2008
Issue release date: April 2009

Number of Print Pages: 11
Number of Figures: 3
Number of Tables: 4

ISSN: 1021-7762 (Print)
eISSN: 1421-9972 (Online)

For additional information: http://www.karger.com/FPL

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.